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ABSTRACT 
Hodgkin lymphoma (HL) is a unique entity among the lymphomas, with a minority of 
malignant Hodgkin and Reed-Sternberg (H-RS) cells surrounded by a broad range of 
infiltrating cells. The infiltration of certain inflammatory cells has been reported to 
predict prognosis of the disease. In HL tumor microenvironment, the primary H-RS 
cells and those inflammatory cells interact interdependently. The aberrant cytokine 
production of H-RS cells has been suggested to contribute to this interdependency. 
However, little is known in terms of the mechanisms involved in the abnormal cytokine 
secretion by H-RS cells. Previous studies suggested that several pro-inflammatory 
molecules likely contribute to the aberrant cytokine secretion of HL, including 
cysteinyl-leukotrienes receptor type I (CysLT1R) and 15-lipoxygenase-1(15-LOX-1) 
that are highly expressed in primary H-RS cells and cultured HL-derived L1236 cells.   
Previous and present studies in cultured HL cells demonstrate that CysLT1R mediates 
transcription and secretion of cytokines, including interleukin (IL)-6, IL-8 and tumor 
necrosis factor-α, upon stimulation by leukotriene D4 (LTD4). This lipid mediator is 
formed from arachidonic acid through the 5-lipoxygenase (5-LOX) pathway and 
several types of inflammatory cells surrounding H-RS cells can produce cysteinyl-
leukotrienes. To depict the intracellular signaling pathways that bridge the LTD4-
CysLT1R ligation to cytokine induction, a mechanistic study was carried out in L1236 
cells. The results demonstrated that the transcription factor early growth response 
(EGR)-1 is involved in the LTD4-triggered cytokine transcriptional induction.  
The regulatory mechanisms implicated in 15-LOX-1 trans-activation in HL have been 
obscure. This study has also assessed the epigenetic modulation of 15-LOX-1 in 
different aspects. The results revealed that signal transducer and activator of 
transcription (STAT)-6 positively regulates 15-LOX-1 transcription by binding to its 
promoter, in which three putative STAT-6 binding motifs are identified to be required 
for full activation. The accessibility of STAT-6 to the 15-LOX-1 promoter is controlled 
by DNA methylation and histone modification. The histone H3 lysine (K)-4 specific 
methyltransferase SMYD3 was found to exhibit an important role in this multi-step 
regulation. Although the H3K27me3 demethylase UTX mediates 15-LOX-1 trans-
activation by H3K27 demethylation upon IL-4 stimulation in lung carcinoma A549 
cells, a crucial histone H3K27-demethylase-independent role of UTX in 15-LOX-1 
transcriptional regulation in L1236 cells was demonstrated.  
In conclusion, this study has evaluated the biology of HL by using in vitro models, 
focusing on lipoxygenases regulation and function. The results not only demonstrated a 
signaling pathway that hypothetically bridges 5-LOX activity to the striking 
inflammatory microenvironment in HL, but also uncovered epigenetic regulation 
mechanisms involved in 15-LOX-1 expression in HL-derived cells. Our findings 
suggest that lipid signaling pathways might play critical roles in HL pathogenesis, thus 
warranting further HL research. 
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LIST OF ABBREVIATIONS 
 
15(S)-HETE  15(S)-hydroxy Eicosatetraenoic acid  
15-LOX-1 15-lipoxygenase-1  
5-Aza 5-Aza-2'-deoxycytidine 
AA Arachidonic acid  
AP-1 Activator protein 1 
BCR B cell receptor  
CCL Chemokine (C-C motif) ligand  
CD Cluster of differentiation 
c-FLIP FLICE-like inhibitory protein 
ChIP Chromatin immunoprecipitation 
CREB cAMP response element-binding protein  
CRISPR Clustered regularly interspaced shortpalindromic repeats 
CSIF Cytokine synthesis inhibitory factor (IL-10) 
CysLTs Cysteinyl-leukotrienes 
DAPI 4′, 6-diamino-2-phenylindol 
DC Dendritic cell 
DDMs DNA demethylases 
DIC Differential interference contrast 
DMEM Dulbecco’s Modified Eagle Medium 
DNA Deoxyribonucleic acid 
DNMTs  DNA methyltransferases  
EDF Eosinophil differentiation Factor 
EGR-1 Early Growth Response 1 
ELISA Enzyme-linked immunosorbent assay 
FOSB  FBJ murine osteosarcoma viral oncogene homolog B 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GATA GATA-binding protein 
GC Germinal center 
HATs Histone Acetyltransferases  
HDACs Histone deacetylases 
HDMs  Histone demethylases 
HL Hodgkin lymphoma  
HMTs Histone methyltransferases 
HnKm Histone Hn lysine m 
HnKmme2 Histone Hn lysine m di-methylation 
HnKmme3 Histone Hn lysine m tri-methylation 
H-RS Hodgkin Reed-Sternberg 
IFNB2 Interferon beta-2 
IgG Immunoglobulin G 
IL Interleukin 
IκBα Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha 
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JMJD3 Histone Demethylase Jumonji D3 
KAT3B Histone acetyltransferase lysine (K)-acetyltransferase 3B  
KDM3A   Lysine-Specific Demethylase 3A 
LPS Lipopolysaccharides 
LT Leukotriene 
MAPK Mitogen-activated protein kinase 
MCP Monocyte chemotactic protein 
MDC Macrophage-derived chemokine 
MIP  Macrophage inflammatory protein 
MSP Methylation-specific PCR  
MUM-1 Multiple Myeloma Oncogene 1 
NAB-2 NGFI-A binding (NAB) proteins member 2 
NCBI National Center for Biotechnology Information 
NEAA Non-Essential Amino Acids 
NF Nuclear factor  
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NHL Non-Hodgkin lymphoma 
NK Natural killer 
NLPHL Nodular lymphocyte predominant Hodgkin lymphoma  
NR4A3 Steroid-thyroid hormone-retinoid receptor Nuclear Receptor Subfamily 
4, Group A, Member 3 
Pax-5 Paired box family of transcription factors, member 5 
PcG Polycomb group  
PCR Polymerase chain reaction 
PRCs Polycomb-Repressive Complexes 
PVDF Polyvinylidene fluoride 
qRT-PCR  Quantitative Real-time PCR 
RANK Receptor Activator of Nuclear Factor κ B 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute 
SAHA Suberoylanilide hydroxamic acid 
SCC Squamous cell carcinoma 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
shRNA Short hairpin RNA 
SMCX  Smcy Homolog, X-Linked 
SMYD3 SET And MYND Domain-Containing Protein 3 
STAT Signal transducer and activator of transcription  
TARC Thymus and activation regulated chemokines 
TNF-α  Tumor necrosis factor-α 
TRIB-1 Tribbles homolog 1 
TrxG Trithorax group 
TSA Trichostatin A 
UTX Ubiquitously Transcribed Tetratricopeptide Repeat Protein X-Linked 
XIAP X-linked inhibitor of apoptosis 
β2m Beta-2 microglobulin 
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1 INTRODUCTION 
 
1.1 HODGKIN LYMPHOMA:  
A cancer with an inflammatory signature 
In 1832, Hodgkin lymphoma (HL) was first described by Thomas Hodgkin[1], and  in 
1865, it was re-described by Samuel Wilks in further detail and later to be called 
Hodgkin’s disease[2]. About 70 years later, Carl Sternberg and Dorothy Reed identified 
a type of giant cells, later termed Hodgkin Reed-Sternberg (H-RS) cells [3]. These cells 
are now considered as the malignant cells in HL. According to the World Health 
Organization classification, HL comprises two entities, nodular lymphocyte 
predominant HL (NLPHL) and classical HL. The classical HL can be further 
subdivided into four subtypes, including nodular sclerosis, mixed cellularity, 
lymphocyte-depleted, and lymphocyte-rich [4, 5]. Hereafter HL refers to classical HL 
unless stated otherwise. 
The identification of HL malignant H-RS cells provides an opportunity for the HL 
biologic and therapeutic research. In this respect, the origin of H-RS cells became 
crucial since it could lead us to understand the pathogenesis of this disease. Although 
the origin of H-RS cells is now identified to be the germinal center (GC) B cells [4, 6-
9], the origin of these particular cells has confused researchers for decades, mainly due 
to the limited number of H-RS cells in HL tumor tissue. The HL tumor tissues contain 
only 1-3% H-RS cells surrounded by abundant inflammatory cells [10]. Moreover, 
mixed hematopoietic cell markers are expressed in H-RS cells, such as the dendritic 
cell associated molecules: restin, fascin and thymus and activation regulated 
chemokines (TARC); Granulocyte and monocyte (CD15), B cells (Pax-5), plasma cells 
(MUM-1, CD138)[4]. Finally, when H-RS cell immunoglobulin rearrangements was 
analyzed by using microdissection and single-cell PCR, the origin of these cells were 
clarified as pre-apoptotic GC B-cells because they were carrying destructive V-gene 
mutations[6, 7, 11], although rare cases are derived from T cells[12-15]. The origin of 
H-RS cells and lymphocytic and histiocytic cells in NLPHL was described 
schematically by Thomas et al[5](figure 1). In GC, most B cells with low B cell 
receptor (BCR) affinity are programmed to die after positive selection, and this cell 
programmed death is mediated by the TNF  
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Figure 1   The origin of the H-RS cell (adapted from RK Thomas, et al.2004. With permission) 
super-family member Fas[16]. However, the H-RS cells survive in absence of selection 
for antigen and lack of expression of the BCR, indicating that these particular cells are 
Fas resistant, which was confirmed previously in cultivated H-RS cells[17]. The 
mechanisms implicated in Fas resistance may potentially be therapeutically 
approachable. The apoptosis escaping mechanism of H-RS cells has been an attractive 
topic. However, addressing somatic mutations of the Fas gene seems not to be a main 
strategy because only 3 of 32 examined cases of HL with proven GC B-cell derivation 
were found to harbor deleterious FAS gene mutations[18, 19]. Several molecules were 
demonstrated to be involved in the anti-apoptotic feature of H-RS cells. Among those, 
X-linked inhibitor of apoptosis (XIAP) [20] and anti-apoptotic c-FLIP [19, 21] has been 
suggested to play important roles in apoptosis resistance.  Additionally, certain pro-
survivor factors such as cytokines and transcription factors are also implicated in H-RS 
cell survival (discussed later). 
A feature that makes this lymphoma unique is the minority of neoplastic H-RS cells 
interspersed in an abundant reactive background of inflammatory cells (figure 2), 
including non-neoplastic B and T lymphocytes, mast cells, eosinophils, plasma cells, 
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and histiocytes/macrophages. Fibroblast-like cells and reticulum cells are also found 
detectable [22]. Among these infiltrating cells, CD4 positive T lymphocytes usually 
predominate and form rosette-like communications with H-RS cells[23]. The H-RS 
cells and the surrounding inflammatory cells are interdependent, and the infiltration of 
macrophages, eosinophils and mast cells has been reported to predict prognosis in some 
but not all studies[24-29]. Indeed, soluble factors such as cytokines, chemokines as 
well as lipid mediators together with surface receptors mediate the specific cellular 
composition of the reactive infiltrate and promote H-RS cell survival[30-33]  .  
 
1.2 THE H-RS CELL 
A master of cytokine production 
Cytokines are small cell-released proteins that have specific effects on the 
communications between cells, including leukocyte recruitment. Several lines of 
evidence suggest that the reactive infiltrating cells in the HL microenvironment are 
recruited by cytokines and chemokines released by H-RS cells, contributing to a 
favorable microenvironment [30, 34-36]. Indeed, H-RS cells and the HL cell lines 
produce a wide array of cytokines and chemokines, which are summarized in table 1. 
 
1.3 THE MOLECULAR SIGNATURE OF H-RS CELLS 
 
1.3.1 Signal transducer and activator of transcription-6, constitutively 
activated in H-RS cells and the L1236 cell line, critical for cell 
survival 
The Signal transducer and activator of transcription (STAT) family, comprises seven 
different members including STAT-1, STAT-2, STAT-3, STAT-4, STAT-5 (STAT-5A and 
STAT-5B) and STAT-6[37]. In primary H-RS cells and HL cell lines, STAT-3[38-40], 
STAT-5[41, 42] and STAT-6[43, 44] are commonly activated, at least in part likely due 
to the multiple cytokines produced by these cells. Among these activated transcription 
factors,  STAT-6 is constitutively phosphorylated in 5 of 5 tested HL cell lines and in H-
RS cells from 25 of 32 (78%) evaluated classical HL cases[44].  
STAT-6 is a mediator involved in the IL-4/IL-13 cascade. Briefly, in response to IL-
4/IL-13, STAT-6 is phosphorylated by the receptor associated Janus kinase, and then 
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forms STAT-6 homo-dimers that translocate to the nucleus where target genes are 
bound and activated (figure 3). IL-13 and the IL-13-specific receptor chain (IL-13Rα1) 
are frequently co-expressed in H-RS cells and HL-derived cell lines[45, 46], suggesting 
that an autocrine loop triggers and maintains constitutively activated STAT-6, which has 
been proven by significant decrease of STAT-6 phosphorylation upon IL-13 
neutralizing antibody treatment of HL cell lines[47]. In the same study, the cell 
proliferation was also affected by antibody-mediated neutralization of IL-13, indicating 
that the IL-13/STAT-6 signaling pathway acts as an important proliferation signal in H-
RS cells and HL cell lines. Lentiviral shRNA-mediated STAT-6 inhibition significantly 
suppressed proliferation and induced apoptosis in L1236 cells [43], further 
demonstrating the crucial role of STAT-6 in HL pathogenesis.  
 
Figure 2   Clinical symptoms and histologic feature of HL 
Additionally, STAT-6 is thought to contribute to the inflammatory features of HL. Our 
preliminary data (not shown) revealed changes of cytokine expression pattern upon 
STAT-6 inhibition, indicating that STAT-6 directly contributes to cytokine transcription. 
Further, STAT-6 is a common transcription factor involved in immune cell 
differentiation including Th2 cells, macrophages and dendritic cells, triggered by IL-4 
stimulation. In human macrophages and dendritic cells, STAT-6 mediates 
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Table 1   Cytokines and Chemokines involved in HL 
Cytokines Aliases General Function HL tumor tissue HL-derived cell lines Functions in HL 
IL-1α 
/IL-1β 
IL-1A 
/IL-1B 
Pro-inflammation, involved 
in host defense[48-50] 
H-RS cells frequently 
express IL-1α (58%-
75%), rarely IL-1β 
(<5%)[51-55]  
HDLM2 secrets  IL-1α, 
KM-H2 mainly 
produces IL-1β[56, 57] 
Fibrosis and sclerosis 
induction[52, 55] 
IL-5 EDF Eosinophil activation[22, 58] Highly expressed in HL tissue (95%)[35, 59] 
Expressed in L-428, 
KM-H2[57, 60] 
Associated with tumor 
eosinophilia[36, 61] 
IL-6 IFNB2 
B cell and plasma cell 
differentiation[62], 
pro-inflammation[63] 
Frequently (from 65% 
to 100%)[64-68] 
L1236, L428, KM-H2, 
HDLM2[57, 65, 69] 
Pro-inflammatory 
infiltration formation 
IL-7 / 
Growth factor for B and T 
cells, involved in activation 
of the immune response[70-
72] 
 IL-7 mRNA expression 
was demonstrated in 
HL (77%)[73] 
IL-7 was detectable in 
L-1236, HDLM-2 and 
KM-H2 cells; very low 
levels in L-540 and L-
428 cells[73, 74] 
Promotes proliferation 
of regulatory T cells[74] 
IL-9 P40 T-cell and mast cell growth factor [75] Positive (50% )[35, 76] 
In L428 by stimulation 
with PHA/PMA[77] 
Growth factor for H-RS, 
infiltration of 
eosinophils and mast 
cells [77, 78] 
IL-10 CSIF Anti-inflammatory cytokine, inhibits Th1 response[79, 80] 
Detected in a variable 
percentage of H-RS 
(21% to 36%)[81, 82] 
Expressed in L1236 
and Ho[69, 81] 
Associated with EBV+ 
HL[81, 82] 
IL-13  B-cell maturation and activation[83] 
IL-13 expressed in H-
RS cells (86% to 
93%)[46, 60, 84] 
Positive in HDLM2, 
L1236, L428 and KM-
H2[44, 60] 
Autocrine growth factor 
for H-RS cells[35, 44-
47] 
TNF-α  
Involved in inflammation, 
tissue remodeling, and 
wound healing[85] 
Detected in primary H-
RS cells (69%)[51, 52, 
67, 86-88] 
Expressed in L1236, 
L428, KM-H2, 
HDLM2 and L540[32, 
57, 67, 69, 87] 
Autocrine effects, 
collagen synthesis[89] 
LT-α  Pro-inflammatory cytokine[90, 91] 
LT-α was detected in 
HL (77%)[35, 67, 86] 
Detected in HDLM-1, 
KMH2, L428 and 
L540[67, 87, 88] 
Autocrine factor  for H-
RS[3] 
TGF-β  
B- and T-cell suppression; 
fibroblast proliferation and 
collagen synthesis[92, 93] 
Expression in H-RS 
cells (61%), mainly in 
NSHL[94, 95] 
Detected in L1236 and 
L428[96, 97] 
Associated with nodular 
sclerosis subtype, 
suppresses T-cell 
activation [95] 
IFN-γ  
Pro-inflammatory cytokine, 
Macrophage differentiation 
and activation; NK and CD8 
T-cell activation[98, 99] 
Expressed in H-RS 
cells (47% tumors) [66, 
100-102] 
Expressed in RS cell 
lines L1236, HDLM2, 
L591 and L1236 but is 
absent in L428[69, 
101] 
Stimulates CXCL10[22] 
CCL1 I-309 Monocyte, NK cells, B cells chemotaxis[103, 104] 
Expressed in HL 
tissue[105] 
mRNA was Detected in 
L540, HDLM2 and 
L428[105, 106]  
Might contribute to the 
pro-inflammatory 
microenvironment  
CCL3 
/CCL4 
MIP-1α 
/MIP-1β 
Recruit Th1 cells , 
monocytes and dendritic 
cells[107, 108] 
Detected in HL tissue, 
higher in MCHL 
subtype[102, 109] 
mRNA detected in 
L1236 cells 
(unpublished data) 
Might contribute to the 
pro-inflammatory 
microenvironment  
CCL5 Rantes 
Recruits monocytes, 
eosinophils, mast cells and T 
cells[110, 111] 
Protein expression in 
the H-RS cells[105]  
All Hodgkin cell lines 
express [105, 106, 112] 
Contributes to the 
recruitment of the 
reactive cells in HL[109, 
112, 113] 
CCL11 Eotaxin 
Attracts eosinophils, 
monocytes, and T-cells[114, 
115] 
Expressed by 
fibroblasts in HL tissue 
(63%)[116] 
Positive in L1236 
cells[116] 
Eosinophil 
accumulation, produced 
by fibroblasts[116] 
CCL13 MCP-4 Recruits monocytes, eosinophils, and T-cells[117] 
 Low protein 
expression in H-RS 
cells[105] 
Positive in L1236 
cells[105] 
Might contribute to the 
pro-inflammatory 
microenvironment in 
HL 
CCL17 TARC 
Attracts Th2 cells, regulatory 
T-cells, basophils, and 
monocytes[118] 
Highly expressed in H-
RS cells (88%)[119, 
120] 
Expressed in all HL 
cell lines[119] 
Likely contributes to 
Th2-like and Treg T 
cells enriched 
surrounding in HL[119, 
121] 
CCL22 MDC Th2 response and regulatory T cell induction[22] 
Most HL cases, 
expression by H-RS 
cells (87%),higher in 
NSHL[102, 122]  
Detected in L1236, 
L428 and L591[105, 
106] 
Likely contributes to 
Th2-like and Treg  T 
cells enriched 
surrounding in HL[3, 
22] 
CXCL8 IL-8 Neutrophils recruitment[123] 
Rarely observed in H-
RS cells, but positive in 
reactive cells[124] 
Detected in L1236 cells 
upon LTD4 
stimulation[32] 
Correlated with 
Neutrophils 
accumulation[3] 
CXCL9 
/CXCL10 
MIG 
/IP-10 Th1 cell recruitment[125] 
Expressed at higher 
levels in HL compared 
to benign lymphoid 
tissues[35] 
Detected in L1236 cells 
and L591[3] 
Associated with EBV+ 
HL infiltration[35] 
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CysLT1 receptor[126] and 15-LOX-1 [127] induction upon IL-4 stimulation. Both the 
CysLT1 receptor and 15-LOX-1 are pro-inflammatory molecules, which will be 
discussed in more detail. 
Apart from STAT family members STAT-3, STAT-5 and STAT-6, several other 
transcription factors were also frequently found in H-RS cell and HL cell lines, 
including NF-κB, GATA-2, NOTCH1 and AP-1 (table 2); among which the NF-κB 
pathway has been well studied and its aberrant activity  is likely attributed to mutations 
in the IκBα gene, amplification of the NF-κB/REL locus, and autonomously active 
CD30, CD40, RANK, as well as Notch 1 signaling pathways[128-137].  
Figure 3  Schematic model of STAT-6 activation 
 
 
1.3.2 The CysLT1 receptor mediates the crosstalk between H-RS cells 
and microenvironment 
LTC4, LTD4, and LTE4, collectively called CysLTs, are lipid mediators derived from 
arachidonic acid (AA) through the 5-LOX pathway. 5-LOX and LTC4 synthase catalyze 
in sequence the conversion of AA to LTC4, which in turn is transported out of the cells, 
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and further converted to LTD4 and LTE4[138]. The biological function of the CysLTs is 
principally mediated by G protein coupled CysLTs receptors named CysLT1 and 
CysLT2 receptor [138, 139] (figure 4). The CysLTs have been considered to contribute 
to the pathogenesis of asthma[140] and other inflammatory disorders [141, 142].  
A previous study showed that functional CysLT1 receptors are expressed in primary H-
RS cells as well as in the HL-derived cell lines L1236 and K-MH2. Stimulation of 
L1236 cells with the CysLT1 receptor agonist LTD4 leads to secretion of tumor necrosis 
factor-alpha (TNF-α), IL-6 and IL-8 [32]. As LTD4-producing cells, such as eosinophils, 
macrophages and mast cells, are part of the HL microenvironment, it is hypothesized 
that aberrant cytokine production by the H-RS cells is mediated via the CysLT1 receptor. 
Thus, the CysLT1 receptor signaling pathways mediating cytokine release is of great 
interest to study. 
 
 
Figure 4  The 5-LOX pathway 
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Table 2  Transcription factors involved in HL pathogenesis 
Transcription Factors involved in Hodgkin Lymphoma Pathogenesis 
STAT-6 
STAT-6 is constitutively phosphorylated in primary H-RS cells (78% of analyzed cases), and HL-
derived cell lines L1236, L428, KM-H2, L540 and HDLM2. Lentiviral mediated STAT-6 specific 
shRNA transfection significantly induces apoptosis in L1236 cells, suggesting that STAT-6 plays a 
critical role in H-RS cell survival [43, 44]. 
STAT-5 
STAT-5 is phosphorylated in 38% of examined HL tumors and data suggests that the phosphorylation 
status of STAT-5 in H-RS cells in HL could be a prognostic marker in HL [41, 42]. 
STAT-3 
STAT-3 is constitutively activated in 87% classical HL cases and most HL-derived cell lines including 
L428 and L1236. Gene knockdown experiments suggested that STAT-3 is essential for cell 
proliferation of these HL cells [38-40]. 
NF-κB 
NF-κB is constitutively up-regulated in H-RS cells, and the results showed that more than 90% H-RS 
cells in all analyzed HL patients were positive, although HL cell lines revealed different activation 
mechanisms. In L428 and KM-H2 cells, the constitutive NF-κB activity correlates with defective 
IκBα, in L1236 and HDLM2 cells, IκBα is associated with p65 and displays an enhanced turnover. 
NF-κB plays a crucial role in H-RS cell survival [143-146]. 
GATA-2 
GATA-2 was detected in 50% of tested HL patient H-RS cells, and in all tested HL-derived cell lines. 
The expression of GATA-2 is specific for HL cells and not seen in NHL cells or normal GC B cells, 
suggesting that GATA-2 is important in establishing the abnormal B-cell phenotype of H-RS cells 
[147, 148]. 
NOTCH1 
Notch1 was detected in all studied H-RS cells from 25 HL patients.  The data revealed that Notch is 
an essential upstream regulator of alternative NF-κB signaling and indicate cross talk between both 
the pathways in H-RS cells [149, 150]. 
 AP-1 
 c-Jun and JunB overexpression is found in all tumor cells of patients with HL. AP-1 works 
synergistically  with NF-κB and stimulates expression of the cell-cycle regulator cyclin D2, proto-
oncogene c-met and the lymphocyte homing receptor CCR7, which are all strongly expressed in 
primary HRS cells[151]. Indicating an important role of AP-1 in lymphoma pathogenesis. 
 
 
1.3.3 15-LOX-1 is highly expressed in primary H-RS cells and the L1236 
cell line 
15-LOX-1, also called arachidonate 15-lipoxygenase (ALOX15), is an enzyme that 
oxygenates polyunsaturated fatty acids and bio-membranes. In healthy subjects, this 
enzyme is predominantly expressed in airway epithelial cells, eosinophils, alveolar 
macrophages, dendritic cells and reticulocytes. Previous studies suggested that 15-
LOX-1 is a pro-inflammatory enzyme that contributes to asthma pathogenesis [31, 152-
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154]. In certain human cancers including colon cancer, oesophageal cancer, and 
pancreatic cancer, the expression of this enzyme is suppressed and has been suggested 
as a tumour suppressor[155-159]. 
In HL tumor tissue, 15-LOX-1 was found to be expressed in primary H-RS cells in 17 
of 20 (85%) investigated biopsies using immunohistochemistry staining [160] (figure 
5). However, this enzyme was rarely detected in Non-Hodgkin lymphoma (NHL) 
tissues [161], suggesting that the expression of 15-LOX-1 in H-RS cells may have 
important diagnostic and therapeutic implication in HL. The few numbers of H-RS 
cells in tumor tissue makes the research of HL difficult, therefore the in vitro models 
become important tools for the study of 15-LOX-1 biology. Among HL-derived cell 
lines, L1236 expresses 15-LOX-1 abundantly, while all other established HL cell lines 
are 15-LOX-1 negative [160].  To understand why this molecule is expressed in H-RS 
cells, knowledge about its transcriptional regulation is crucial. 
 
 
 
 
Figure 5    Primary H-RS and L1236 cells express 15-LOX-1. A, probed by 15-LOX-1 specific 
primary antibody, B, isotype controls. (Adapted from Claesson HE, et al. 2008, with permission) 
 
 
 
 
Primary H-RS cells  L1236 cells 
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1.4 TRANSCRIPTIONAL REGULATION 
Background for understanding 15-LOX-1 regulation 
Epigenetic is a definition relative to genetic, which refers to the genetic material DNA 
dependent inheritance that only concerns the DNA sequences information. In 
comparison, epigenetic is the heritable changes in gene activities which are not caused 
by changes in the DNA sequence. DNA decides the genotype, while epigenetic 
regulation controls the phenotype.  
 
Figure 6    Schematic histone structure and modifications 
 
 
The basic components of chromatin are genomic DNA and histone. Histone is a group 
of small proteins including H1, H2A, H2B, H3, and H4, which tightly bind to DNA and 
form nucleosome in eukaryotic cell nucleus, in which two copies of histone H2A, H2B, 
H3, and H4 assemble the core of nucleosome, and the one histone H1 locks DNA and 
histone as soon as the nucleosome is formed[162, 163]. The gene transcription process 
requires the double strand DNA to come apart temporarily, so that transcription factors 
and RNA polymerase are able to access to the gene promoter and the DNA template. It 
is therefore important for cells to have means of unwinding chromatin to permit 
transcription to proceed. Several mechanisms are involved in chromatin remodeling 
that controls gene transcription, including DNA methylation and histone modification. 
Histone modification is a group of events that comprises lysine acetylation, lysine and 
arginine methylation, serine and threonine phosphorylation, and lysine ubiquitination 
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and sumoylation. 
Collectively, gene transcription is regulated by multiple factors including gene 
activators and suppressors. In order to access to target DNA, these factors have to find 
their binding motifs in loosened DNA regions in the genome. Chromatin remodeling 
regulators such as DNA methyltransferases (DNMTs) /demethylases (DDMs), histone 
methyltransferases (HMTs)/demethylases (HDMs), histone acetyltransferases 
(HATs)/deacetylase (HDACs) are important to open or close the chromatin. Thus the 
chromatin remodeling regulators and gene transcription factors are working 
sequentially or synergistically to control gene activation.  
 
1.4.1 DNA methylation 
DNA is composed of four nucleotides comprising adenine (A), thymine (T), guanine (G) 
and cytosine (C), and among these nucleotides cytosine or adenine can be further 
modified by adding a methyl group when needed. Generally, DNA methylation 
typically occurs in a so called CpG Island. DNA methylation is controlled by two 
classes of enzymes termed DNMTs and DDMs. Although little is known about DNA 
DDMs so far, DNMTs are well studied. Three active DNMTs have been identified in 
mammals, named DNMT1, DNMT3A, and DNMT3B[164]. The CpG Island 
methylation displays a wide variety of biological functions in development[165], aging 
and cancers[166, 167]. In the present study, CpG Island methylation at the 15-LOX-1 
promoter region is shown to be implicated in STAT-6 accessibility regulation, thus 
controlling the gene transcription in HL cell lines. More details are described in results 
and discussion. 
 
1.4.2 Histone modifications 
Histone modifications consist of lysine acetylation, lysine and arginine methylation, 
serine and threonine phosphorylation, and lysine ubiquitination and sumoylation, 
among which lysine acetylation and lysine methylation have been widely investigated. 
In the following paragraphs, histone lysine acetylation and lysine methylation will be 
discussed.  
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1.4.3 Histone acetylation 
Histone acetylation is achieved by introducing an acetyl group to lysine residues on 
histone proteins. Histone acetylation is regulated by HATs and HDACs. The 
introduction of acetyl groups is mediated by HATs, which consist of GNAT, MYST and 
p300/CBP subfamilies [168], whereas acetyl groups can be removed by HDACs that 
include class I, II, III and IV subgroups in mammals cells [169]. Histone acetylation 
diminishes the electrostatic affinity between histone proteins and DNA, thereby 
promoting gene transcription [170]. Several lysine residues on the histone N-terminal 
tails can be modified. In our current work, we found that histone H3 hyperacetylation 
was correlated with high 15-LOX-1 expression in L1236 cells, in which an H3 
acetylation-enriched15-LOX-1 promoter is permissive for STAT-6 binding, while in 
L428 cells, the hypoacetylated promoter has low accessibility that inhibits gene 
activation[171]. 
 
1.4.4 Histone lysine methylation 
Histone methylation is a critical epigenetic mechanism involved in embryonic 
development, immune responses, and cancer genesis. Histone methylation plays a 
pivotal role in the maintenance of both active and suppressed states of gene expression 
depending on the sites of methylation. Methylation of histone H3 at lysine (K)-4, 
H3K36, H3K79 is an activation sign of gene transcription, whereas methylation of 
histone H3K9, H3K27 and H4K20 is implicated in suppression of gene 
transcription[172-177]. Histone methylation is catalyzed by HMTs and HDMs, as 
described below (Figure 7). 
 
1.5 TRANSCRIPTIONAL REGULATION OF THE 15-LOX-1GENE 
Several mechanisms are involved 
The Th2 cytokines IL-4 and IL-13 induce the expression of 15-LOX-1 in certain human 
cells, such as human monocytes [178, 179], human umbilical vein endothelial 
cells[180], orbital fibroblasts[181], SCC 1483 oral cavity cancer cells[182] and lung 
epithelial carcinoma A549 cells[183]. The classical IL-4/IL-13 triggered STAT-6 
pathway is involved and plays an important role in 15-LOX-1 induction by directly 
binding to the promoter [184, 185]. However, the STAT-6 activation is not sufficient to 
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induce15-LOX-1 expression in dermal fibroblasts [181] and the human monocytic cell 
line THP-1 cells [183]. Moreover, the HDAC inhibitor suberoylanilide hydroxamic 
acid (SAHA) suppresses STAT-6 expression, but on the other hand stimulates the 
expression of 15-LOX-1[186], indicating that also other pathways are involved in the 
transcriptional activation of the gene. 
 
Figure 7  Histone lysine modifications and key regulators. Histone lysine methylation is a major 
epigenetic regulation of gene transcription both positively and negatively. Many histone modifiers have 
been identified. Lysine methylation has been implicated in both transcriptional activation (H3 Lys4, 36, 
79) and silencing (H3 Lys9, 27, H4 Lys20) (Illustration modified from Cell Signaling Technology, Inc. 
www.cellsignal.com with a permission). 
 
In human monocytes, apart from the STAT-6 pathway, an important regulatory role of 
ERK1/2 was demonstrated, ERK1/2 mediates IL-13-induced 15-LOX-1 expression via 
the transcription factors early growth response (EGR)-1 and cAMP response element-
binding protein (CREB)[179]. Several other factors are suggested to be important in IL-
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4 induced 15-LOX-1 expression, including activator protein 2, GATA motif-binding 
transcription factor (GATA)1, nuclear factor (NF)1, SP-1[180] and vimentin[187], 
while GATA-6 is a suppressor of 15-LOX-1 in colorectal cancer cells [188, 189]. 
Interestingly, the Th1 cytokine INF- γ has negative effects on 15-LOX-1 induction, 
indicating that this enzyme is a Th1 and Th2-counterregulated-mediator [190, 191]. The 
promoter methylation of DNA by DNA DNMTs in CpG-rich regions has been well 
described as a critical component of epigenetic silencing in human cells. DNA CpG 
methylation is also involved in the regulation of 15-LOX-1 transactivation.  In 
colorectal cancer, promoter methylation of 15-LOX-1 was detected both in vivo and in 
vitro and has been suggested to contribute to the 15-LOX-1 expression inhibition, [192]. 
The association of hypermethylated promoter and 15-LOX-1 suppression was also 
demonstrated in HL cell lines [193]. Interestingly, another study suggested that the 
DNMTs can inhibit 15-LOX-1 transcription by a DNA methylation-independent 
mechanism [192]. Moreover, in prostate cancer cells, promoter hypermethylation has 
been suggested to promote 15-LOX-1 expression [194]. Thus, different mechanisms are 
operating in different cell types. This might be due to the fact that different types of 
cells express different transcription factors.   
Histone modification is another type of epigenetic regulation involved in development, 
cancer and other diseases (see also above). Recent experimental evidence revealed that 
histone modification also plays a crucial role in 15-LOX-1 transcriptional regulation. 
H3K9me2 demethylation catalysed by lysine (K)-specific demethylase 3A (KDM3A) 
transcriptionally activates 15-LOX-1 in colorectal cancer cells. Moreover, histone H3 
and histone H4 acetylation mediated by histone acetyltransferase lysine (K)-
acetyltransferase 3B (KAT3B) is also implicated in 15-LOX-1 transcriptional 
activation [195].  The association of histone acetylation with 15-LOX-1 expression was 
also found in the HL cell line L428 cells. In these cells, the transcription of 15-LOX-1 
was induced only after stimulation with both trichostatin A (TSA) and 5-Aza [193], 
indicating that histone acetylation and DNA methylation synergistically regulate gene 
transcription. 
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2  AIMS OF THE STUDY 
 
HL is one of the most common malignant disorders among young adults. Although the 
disease is largely curable, improved and targeted treatment with less early and late side 
effects is urgently needed. The inflammatory microenvironment in HL is a unique 
feature of this disease; therefore an understanding of the molecular mechanisms 
involved in the inflammatory component of HL is of great interest and of potential 
importance for the development of future more specific treatment. Two inflammation-
related molecules, CysLT1 and 15-LOX-1, are highly expressed in primary H-RS cells 
and the HL cell line L1236.  
 
This study specifically aims to: 
 
1. Characterize the functional role of the CysLT1 receptor in the pathogenesis of 
HL, focusing on the signaling pathways that bridge the LTD4 stimulation to 
cytokine induction.  
 
2. Elucidate the involvement of constitutively activated STAT-6 in the expression 
of 15-LOX-1 in HL cell lines, and eventually understand the mechanism of 15-
LOX-1 expression in primary H-RS cells. 
 
3. Appraise the role of epigenetic regulation in 15-LOX-1 transcription in HL-
derived cells. 
 
a. Delineate promoter CpG methylation in 15-LOX-1 transcriptional 
activation 
b. Evaluate the involvement of histone acetylation in 15-LOX-1 transcription 
c. Assess the histone methylation mediated by SMYD3 and UTX in 15-LOX-
1 transactivation 
d. Define the cooperation of DNA methylation, histone modification and 
transcription factor in 15-LOX-1 transactivation regulation. 
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3  MATERIALS AND METHODS 
 
3.1 EXPERIMENTAL MATERIALS 
 
3.1.1 HL Biopsies and Cell lines 
HL tumor tissue was collected from lymph node biopsies and the studies on patient 
samples were approved by the local ethics committee. The HL-derived cell lines L1236 
(so far the only Hodgkin cell line formally shown to be derived from H-RS cells), L428 
and KM-H2 cells were used in the present study, and all three HL cell lines were kind 
gifts from Professor Volker Diehl, Cologne, Germany. The human lung epithelial 
carcinoma A549 cell line was used as a 15-LOX-1 inducible cell model for studying 
epigenetic regulation. A549 cells were purchased from Leibniz-Institute DSMZ-
German Collection of Microorganisms and Cell Cultures, Brunswick, Germany. 
Another 15-LOX-1 positive cell line was used in this study, the human prostate 
adenocarcinoma cell LNCaP and this cell line was purchased from the American Type 
Culture Collection, Manassas, VA. Detailed information on the studied cell lines is 
listed in table 3. 
Table 3   Cell lines used in the study 
Cell lines L1236 L428 KM-H2 LNCaP A549 
Derivation HL (MC) HL (NS) HL(MC to LD) human prostate 
adenocarcinoma 
lung epithelial 
carcinoma 
Specimen site peripheral blood pleural effusion pleural effusion lymph node  epithelial cells 
Cell type B-cell type B-cell type B-cell type epithelial cells epithelial cells 
Patient 34-year-old male 37-year-old female 37-year-old male 50-year-old male 58-year-old male 
15-LOX-1 Positive Negative Negative Positive Inducible 
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3.2 METHODS 
3.2.1 SYBR Green-Based Quantitative Real-Time PCR 
Quantitative Real-time PCR (qRT-PCR) is a technique which is a major development 
of the polymerase chain reaction that enables reliable detection and measurement of 
gene transcription levels. The material needed for this method is achieved through total 
RNA extraction. The basic theory of qRT-PCR is to use fluorescence to detect the 
threshold cycle (Ct) during PCR when the level of fluorescence gives a signal over the 
background and is in the linear portion of the amplified curve. This Ct value is used for 
the accurate quantization of qRT-PCR. The SYBR Green is an asymmetrical cyanine 
dye that intercalates with double-stranded DNA, which introduces fluorescence of the 
SYBR. The qRT-PCR machine detects the fluorescence and the software calculates Ct 
values from the intensity of the fluorescence. All qRT-PCR performed in this study was 
carried out in an ABI 7900HT real-time PCR thermo cycler using pre-designed primers 
(all detailed primer sequences used in this study can be found in the attached papers). 
The levels of gene transcription were calculated by using the 2(-Delta Delta Ct) Method 
[196]. The house keeping genes Beta-2 microglobulin (β2m) and Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) were used as loading controls. 
3.2.2 Western blot 
Western blot is a protein detection method based on antibody-antigen specific 
recognition. In this study, whole cell lysate was prepared, followed by SDS-PAGE 
electrophoresis and subsequent transfer to PVDF membranes. The membranes were 
then probed by antibodies against the target proteins. Horseradish peroxidase 
conjugated secondary anti-mouse or rabbit IgG were used to detect the enrichment of 
the target protein by developing with the enhanced chemiluminescent method. Beta-
actin was used as a loading control. In this study we applied this method to detect the 
target proteins including EGR-1, STAT-6, 15-LOX-1, SMYD3, SMCX, UTX and β-
ACTIN (more details in the constituent papers). 
3.2.3 15-LOX-1 activity assay 
In order to measure the catalytic activity of 15-LOX-1, the concentration of 15(s)-
hydroxy eicosatetraenoic acid (15(S)-HETE) was measured by ELISA. 15-LOX-1 
catalyzes the conversion of AA to 15(S)-HETE which is the major mediator formed 
through this pathway. Briefly, the L1236 cells were harvested and washed by PBS 
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followed by centrifugation. The cell pallet was re-suspended in PBS. The cells were 
then incubated in a 37°C water bath with AA for 5 minutes and subsequently put on dry 
ice to stop the reaction. The concentration of 15(s)-HETE in the supernatant was used 
as a biomarker for activation of this pathway.  
3.2.4  Immunofluorescence 
Immunofluorescence is another immune-recognition-based technique that is commonly 
used for detection of the target molecule. Basically, this technique applies the 
specificity of antibodies to their antigen, and specifically targets fluorescent dyes to the 
molecules as desired. There are two main methods of immunofluorescence including 
direct and indirect immunofluorescence. The more frequently used method is the 
indirect immunofluorescence, whereby the primary antibody specifically recognizes the 
molecule of interest, and the primary antibody is then targeted by a second anti-
immunoglobulin antibody that is tagged with the fluorochrome. Under excitation light, 
the fluorochrome expresses emission light that can be captured by microscope-mounted 
camera.   
3.2.5 Chromatin Immunoprecipitation Assay      
The chromatin immunoprecipitation (ChIP) assay is also an antibody-antigen based 
technique that is commonly used for probing protein-DNA interactions within the 
natural chromatin context of the cell. The ChIP assay can be used to assess the histone 
modification status during gene expression regulation and to determine the binding of 
transcription factors and other DNA interaction proteins. Briefly, the cells were fixed 
directly in the culturing medium by adding formaldehyde to a final concentration of 1% 
(fixation may not be needed when studying histone modification), which reversibly 
preserved the protein-DNA interaction occurring in the cells under certain conditions. 
The cells were then lysed and chromatin isolated and fragmented using sonication. The 
chromatin was then subjected to immunoprecipitation using antibodies specific to a 
particular protein or modified histone of interest to pull down the DNA sequences that 
are associated with the particular protein or histone modification. After 
immunoprecipitation, the protein-DNA cross-links were reversed and the DNA purified. 
The enrichment of a particular DNA sequence can be detected by quantitative PCR.  
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3.2.6 Luciferase Reporter-Based Promoter Activity Assay 
The luciferase reporter based promoter activity detection system is basically 
constructed by the promoter of interest followed by the firefly luciferase coding region. 
This luciferase reporter-based system provides an intracellular tool for quantitatively 
studying the cis- or trans-regulating elements that putatively modulate gene expression. 
To determine the regulation of the promoter of interest, the reporter vector is 
transfected into certain cells. Simultaneously, the Renilla reniformis luciferase-
containing vector is co-transfected as a loading control that normalizes the transfection 
handling error.  
3.2.7 Lentiviral Transduction System for Gene Knock-down 
A potent approach to transduce cells is the use of virus derived vectors, among which 
the lentiviral vector (derived from HIV-1) is a widely used vector that is able to 
transduce both dividing and non-dividing cells as the viral preintegration complex can 
get through the intact membrane of the nucleus in the target cell. Lentiviral vectors are 
usually created in a transient transfection system, in which the packaging cells (the 
HEK293FT cells were used in this study) are transfected with three different plasmids, 
including a transfer vector plasmid (pLKO.1 and pGIPZ were used in this study), a 
packaging plasmid (psPAX2 was used in this study) and a envelop plasmid (pMD2.G 
was used in the present study).  The virus particles are then produced and released to 
the supernatant that is used to transduce the cells of interest. The transfer vector can be 
used both to over-express and knock-down target gene depending on the aim of the 
study. In the present study, the pGIPZ was used for EGR-1 knock-down and the 
pLKO.1 was used for UTX knock-down.  
3.2.8 Microarray Gene Expression Analysis 
Microarray gene expression analysis is a technique for gene profiling, which enables 
high-throughput gene expression quantification on a small chip. This method has been 
developing though the recent decades, and it is widely used for screening for candidate 
disease-associated transcripts, diagnostic markers and therapeutic targets.  Microarray 
is also very useful for investigating signaling pathways. Total RNA preparation is 
required to initiate the microarray analysis. The high quality total cellular RNA is 
subsequently converted to cDNA or cRNA that hybridizes with tagged DNA probes in 
each DNA spot on the chip. The probe-target hybridization is usually detected and 
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quantified by fluorescence intensity that represents the abundance of gene transcripts. 
In this study the affymetrix Human Gene 1.0 ST Array was performed. The gene 
transcription fold change was analyzed by comparing the LTD4 treated L1236 cells 
versus controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26 
4   RESULTS AND DISCUSSION 
 
4.1 H-RS CELLS EXPRESS THE CYSLT1 RECEPTOR THAT MEDIATES 
CYTOKINE AND CHEMOKINE EXPRESSION VIA THE 
TRANSCRIPTION FACTOR EGR-1 
Accumulating data reveal that the H-RS cells and the infiltrating cells are 
interdependent. The H-RS cells secret an abundance of cytokines and chemokines that 
recruit inflammatory cells to the tumor sites. The infiltrating cells in turn produce 
different growth factors to form a favorable microenvironment for the H-RS cells [11, 
30, 35, 36, 74, 113, 197-201]. To understand the crosstalk between H-RS cells and the 
bystander cells, knowledge about the mechanisms leading to H-RS cell 
cytokine/chemokine production is crucial. Our previous studies have uncovered part of 
these mechanisms; by immunohistochemistry in formalin-fixed paraffin-embedded 
tissue, CysLT1 receptor expression was noted in H-RS cells in 12 out of 20 HL patients 
and the expression of CysLT1 receptors was also confirmed by microarray analysis in 
microdissected primary H-RS cells [32]. This finding was of great interest since the 
CysLT1 receptor is a high affinity receptor for LTD4, which presumably is released by 
eosinophils, macrophages and mast cells in the HL tumor microenvironment. In the 
same study referenced above, L1236 cells were studied as a mechanistic model of the 
H-RS cells since the CysLT1 receptor is also expressed by these cells (Figure 8). 
 
Figure 8  Primary H-RS cells express the CysLT1 receptor 
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Interestingly, LTD4 stimulation significantly induced the release of certain cytokines 
including IL-6, IL-8 and TNF-α in a dose-dependent fashion. In the present study, we 
have checked the transcription level of these cytokines upon LTD4 treatment. Not 
surprisingly, the mRNA levels of IL-6, IL-8 and TNF-α were also dose- and time-
dependently induced upon LTD4 stimulation. The expression and release of the 
cytokines were mediated by the CysLT1 receptor since a specific receptor antagonist 
against CysLT1 blocked the action of LTD4 on cytokine release. IL-8 is an important 
inflammatory chemokine that specifically induces chemotaxis of neutrophils. Thus, 
release of IL-8 by the H-RS cells may recruit neutrophils into the tumor site. TNF-α is 
another important inflammatory mediator, which promotes the synthesis of other 
proinflammatory compounds by various cell types [35]. Therefore, we demonstrated 
the grounds for a paracrine loop that partially may depict the interdependency between 
H-RS cells and infiltrating inflammatory cells. Furthermore, two other chemokines, 
Mip-1α and Mip-1β, were also induced upon LTD4 stimulation. Mip-1α and Mip-1β 
are also named CCL3 and CCL4, both of which are chemoattractants for T cells and 
monocytes and were detected in HL tumor tissues [35]. 
The interesting finding of the LTD4/CysLT1-cytokine axis in HL provides the CysLT1 
receptor as a potential target in HL therapy that warrants further attention. However, the 
intracellular signaling pathway(s) bridging the CysLT1 receptor activation to cytokine 
induction is (are) still unclear. In order to delineate the picture of the signaling 
pathways triggered by LTD4 stimulation, microarray profiling was performed. Several 
transcription factors were identified and verified to be induced by LTD4 through the 
CysLT1 receptor, including EGR-1, NGFI-A binding (NAB) proteins member 2 (NAB-2), 
steroid-thyroid hormone-retinoid receptor Nuclear Receptor Subfamily 4, Group A, Member 3 
(NR4A3), FOS protein B (FOSB), as well as Tribbles homolog 1 (TRIB-1), which gave us an 
idea about how LTD4-CysLT1 ligation leads to cytokine trans-activation in H-RS cells. 
Among these factors, we further studied the transcription factor EGR-1 that has been 
proved to be a critical mediator of LTD4 triggered cytokine transcription [202]. The 
results demonstrated that EGR-1 is required for expression of IL-6, TNF-α, Mip-1α and 
Mip-1β, but the induction of IL-8 was not affected by EGR-1 knockdown, indicating 
that alternative pathways are involved in IL-8 induction upon LTD4 stimulation. Recent 
studies revealed that LTD4 initiates activities through robust induction of multiple 
signaling pathways in human cells. These pathways are mediated in part by activation 
of mitogen-activated protein kinase (MAPK), which in turn activates a large number of 
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transcriptional regulators including EGRs and AP-1. Thus, the MAPK pathway might 
be involved in LTD4 induced EGR-1 activation. Downstream targets of EGRs and AP-
1 include multiple inflammatory cytokines that might contribute to LTD4–
pathophysiology [203-206]. 
In addition to EGR-1, the FOSB, a member of the Fos family (c-Fos, FOSB, Fra-1, and 
Fra-2) was induced dramatically at the transcriptional level in L1236 cells upon LTD4 
challenge. Fos family members combine with Jun family members (c-Jun, JunB, and 
Jun D) [207], to form the transcriptional factor AP-1. AP-1 is a pro-inflammatory 
transcription factor that might be implicated in IL-8 induction in L1236 cells since IL-8 
was induced through AP-1 in HEK293 cells stably transfected with CysLT1 and 
stimulated with LTD4 [208]. However, EGR-1 knockdown only partially inhibited the 
cytokine induction, reflecting either that additional pathways are involved or 
insufficient RNA interference efficiency. NR4A3 and TRIB-1 were also identified as 
early response genes upon LTD4 stimulation. Both of NR4A3 [209-211] and TRIB-
1[212] have been shown to be involved in inflammation and cancer. Identification of 
the target genes of AP1, NR4A3 and TRIB-1 might further depict the role of the 
CysLT1 receptor in the pathogenesis of HL. Based on the overall results, a mechanistic 
model of LTD4-induced signaling in H-RS cells is proposed (figure 9). 
 
Figure 9   Schematic model of LTD4-mediated signaling in L1236 cells 
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Apart from L1236 cell, the HL cell line KM-H2 was also reported in our previous study 
to express CysLT1 [32]. The cytokine induction pattern upon LTD4 stimulation was 
slightly different from L1236 cells, which might be explained by different origin of 
these two cell lines. A possible pathophysiological role of the CysLT1 receptor in HL 
has been suggested (figure 10), as summarized above, the signaling pathway triggered 
by LTD4 was also partially depicted (Figure 9). However, it must be considered that not 
all tumors exhibit H-RS cells expressing the CysLT1 receptor, emphasizing the 
complexity of the mechanisms underlying the inflammatory feature of HL.  
 
 
 
 
 
Figure 10   The CysLT1 receptor mediates cytokine production that 
contributes to HL-microenvironment – a hypothetical model 
 
4.2 STAT-6 IS REQUIRED FOR 15-LOX-1 ACTIVATION IN L1236 CELLS 
STAT-6 is constitutively activated in primary H-RS cells as well as cultured L1236 
cells. This abnormal activation attributes to IL-13/IL-13R mediated autocrine 
stimulation [47, 200]. As mentioned above, primary H-RS cells and L1236 cells 
express 15-LOX-1, of which the promoter contains three putative STAT-6 binding 
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motifs. Thus the question we would like to ask and to answer was: Dose constitutively 
activated STAT-6 stimulate 15-LOX-1 expression in H-RS cells?  
The classical tool for investigating trans-activation of promoters is a luciferase-based 
promoter reporter. Therefore, a 1081 base pair long fragment from the 15-LOX-1 
promoter was cloned into the luciferase reporter vector pGL3-basic. After transfection 
into L1236 cells, luciferase activity was measured and used as an indicator of 
transcriptional activity. In order to pinpoint transcriptionally important regions, series 
of 5’-deletion constructs were produced in pGL3-basic reporter vectors. The luciferase 
activity indicated that the region from − 1003 to – 866 including two predicted STAT-6 
binding sites was found to be essential for transcription.  
To specifically elucidate the contribution of STAT-6 to 15-LOX-1 transcription, three 
mutant plasmids were created by site-directed mutagenesis of pGL3-wt at three 
putative STAT-6 binding motifs. The results indicated that all three putative STAT-6 
binding sites are required for full 15-LOX-1 transcription in L1236 cells. Further, we 
assessed the association of STAT-6 with the 15-LOX-1 promoter. The results showed a 
physical interaction of STAT-6 and the promoter of 15-LOX-1. The critical role of 
STAT-6 in 15-LOX-1 expression was verified by STAT-6 siRNA knockdown 
experiments, in which 15-LOX-1 mRNA transcription was remarkably reduced by 
STAT-6 specific siRNA transfection compared to control siRNA. 
In conclusion, constitutively activated STAT-6 contributes to the highly expressed 15-
LOX-1 in L1236 cells, in which STAT-6 is recruited at the 15-LOX-1 promoter to 
STAT-6 binding motifs. As the L1236 cell line has been proved to be derived from 
primary H-RS cells, it is considered likely that 15-LOX-1 expression also in primary 
H-RS cells is attributable to STAT-6. However, in another HL cell line, L428, 15-
LOX-1 is not expressed despite STAT-6 being activated also in this cell line. 
Additional regulatory factors therefore likely exist in 15-LOX-1 trans-activation.  
4.3 EPIGENETIC MODIFICATIONS CONTROL STAT-6 ACCESSIBILITY 
THAT REGULATES 15-LOX-1 EXPRESSION IN HL CELLS 
To identify the factors that cause the different expression pattern of 15-LOX-1 in HL 
cell lines L1236 and L428 the following experimental setup was used.  The promoter of 
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15-LOX-1 in both HL cell lines was sequenced and blasted in NCBI. No mutation was 
detected indicating that epigenetic regulation is likely playing a critical role in 15-LOX-
1 gene activation. STAT-6 has been shown to be recruited to the 15-LOX-1 promoter 
and activating the gene transcription in L1236 cells. Interestingly, ChIP analysis 
revealed no binding of STAT-6 at the 15-LOX-1 promoter in L428 cells, suggesting 
that STAT-6 accessibility is suppressed in this particular cell. Notably, a previous study 
demonstrated the importance of DNA methylation and histone acetylation in 15-LOX-1 
expression in L428 cells, in which the co-stimulation of 5’-azadeoxycytidine (DNA 
methyltransferase inhibitor) with either IL-4 or trichostatin (HDAC inhibitor) induces 
15-LOX-1 transcription [193], meaning that DNA methylation and histone acetylation 
of the 15-LOX-1 promoter are involved in 15-LOX-1 expression in HL cells. Thus, the 
methylation status of the 15-LOX-1 promoter was determined with methylation-
specific PCR (MSP). The results revealed that the 15-LOX-1 promoter region is 
hypomethylated in L1236 cells while hypermethylated in L428 cells. Therefore, our 
data suggest a strong correlation of the 15-LOX-1 promoter methylation pattern with 
STAT-6 accessibility and 15-LOX-1 gene activation in cultured HL cells. 
We and others previously showed that histone acetylation was involved in 15-LOX-1 
transcription. The acetylated H3 is a sign of gene activation; therefore, ChIP assay was 
employed to compare the acetylation status of histone H3 at the 15-LOX-1 promoter in 
both HL cell lines. Histone H3 hyperacetylation was demonstrated in the 15-LOX-1 
promoter region in L1236 cells, while hardly detectable in L428 cells. Collectively, 
these data suggested a correlation of 15-LOX-1 promoter CpG island methylation and 
histone acetylation status with STAT-6 accessibility and 15-LOX-1 gene activation in 
cultured HL cells.  
However, in prostate cancer cells, the hypermethylation of specific CpG island in the 
15-LOX-1 promoter leads to the upregulation of 15-LOX-1 expression [194]. 
Moreover, lack of correlation between promoter methylation and expression of the 15-
LOX-1 gene was reported in colorectal cancer cell line and primary tumor specimens 
[192]. Additional or alternative epigenetic controlling mechanisms are therefore likely 
involved in 15-LOX-1 gene activation.  
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4.4 HISTONE H3 LYSINE 4 METHYLATION/DEMETHYLATION 
CONTROLS 15-LOX-1 TRANSCRIPTION IN HL CELL LINES 
To seek the additional epigenetic mechanism(s) involved in 15-LOX-1 transcriptional 
regulation, we focused on histone methylation that has dual effects on gene activation 
and suppression, depending on the precise residues and levels of methylation [213]. In 
particular, H3K4me3 and H3K4me2 associate with gene activation. We compared the 
methylation status of the 15-LOX-1 promoter in the two HL cell linesL1236 and L428 
by using ChIP assay.  The results showed remarkably higher H3K4me3 levels in L1236 
cells compared to L428 cells, suggesting that the H3K4me3 level is positively 
correlated with 15-LOX-1 expression in HL cell lines. 
Because histone methyltransferase SMYD3 and histone demethylase SMCX are major 
H3K4 methylation modifiers, we hypothesized that they might be responsible for H3-
K4 methylation/demethylation at the 15-LOX-1 promoter, thereby regulating 15-LOX-
1 gene transcription. RT-PCR and immuno-blotting demonstrated that SMYD3 was 
highly expressed in L1236 cells but not present in L428 cells, while SMCX was only 
detectable in L428 cells. Furthermore, SMYD3 inhibition reduced 15-LOX-1 
expression by decreasing promoter activity in L1236 cells. SMYD3 knocking down in 
these cells abolished trimethylation of H3-K4, coupled with diminished occupancy by 
STAT-6, and histone H3 acetylation at the 15-LOX-1 promoter. In contrast, inhibition 
of SMCX led to upregulation of 15-LOX-1 expression through induction of H3-K4 
trimethylation, histone acetylation and STAT-6 recruitment at the 15-LOX-1 promoter 
in L428 cells. Interestingly, a putative SMYD3 binding site was identified in the 15-
LOX-1 promoter. Introduction of a point mutation in the site remarkably affected the 
activity of the 15-LOX-1 promoter in L1236 cells. In addition, we observed strong 
SMYD3 expression in the prostate cancer cell line LNCaP and its inhibition led to 
decreased 15-LOX-1 expression. Taken together, the status of histone 
methylation/demethylation at the 15-LOX-1 promoter is critical in controlling 15-LOX-
1 expression. 
Taken together, it seems that the chromatin remodeling is a critical “pre-cleaning” step 
for transcription factors finding their binding sites. In the 15-LOX-1 negative cell line 
L428, the 15-LOX-1 promoter region is occupied by HDM SMCX. The promoter is not 
accessible to STAT-6 due to the hypomethylation of H3K4 and the hypoacetylation of 
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H3, and thus the transcription of 15-LOX-1 is inhibited. Suppression of SMCX results 
in increased H3K4 methylation and leads to transcriptional activation of the 15-LOX-1 
gene transcription (Figure 11, left panel). In L1236 cells, the 15-LOX-1 promoter is 
associated with SMYD3 coupled with hypermethylation of H3K4 and consequently 
activated 15-LOX-1 gene transcription (Figure 11, right panel).. Notably, these results 
suggested that chromatin modifiers and transcriptional factors either work sequentially 
or synergistically to strictly control the expression of genes important for cell 
differentiation and survival.  
 
Figure 11   schematic model of 15-LOX-1 activation on HL cell lines 
 
4.5 UTX MEDIATES IL-4/IL-13 INDUCED 15-LOX-1 EXPRESSION 
IL-4 triggers mRNA transcription and protein expression of 15-LOX-1 in A549 cells 
and human monocytes (Figure 12) [178, 179]. Furthermore, highly expressed 15-LOX-
1 in HL primary H-RS cells as well as in cultured L1236 cells [171, 185, 193] was 
thought to result from IL-13 autocrine stimulation. However, while binding of the 
cytokine to its cognate surface receptor is required for gene expression, it is not 
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sufficient in all cells expressing functional IL-4 receptors, indicating more complex 
mechanisms to be involved in the induction process. In order to address the specific 
mechanisms, A549 cells were established as a model for inducible 15-LOX-1 gene 
expression. 
 
 
 
 
 
 
Figure 12  The transcription of 15-LOX-1is induced by IL-4. 
(A)A549 cells and (B) human monocytes 
To delineate the uncovered mechanisms in IL-4 induced 15-LOX-1 expression, we 
focused on the suppressive histone modification H3K27 methylation, which has been 
A 
B 
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implicated in IL-4 mediated macrophage differentiation. We examined the H3K27 
trimethylation level of the 15-LOX-1 promoter upon IL-4 stimulation [214]. The ChIP 
results showed that the non-IL-4-treated A549 cells exhibit relatively high levels of 
H3K27me3 in the proximal promoter region of 15-LOX-1, and that IL-4 treatment 
substantially reduced the H3K27me3 level in these regions, indicating that histone 
H3K27 demethylation is correlated with 15-LOX-1 transcriptional induction. Tri-
methylation of H3K27 is a repressive marker of gene transcription, which is mediated 
by Polycomb-Repressive Complexes (PRCs) [215]. In untreated A549 cells, 15-LOX-1 
is not expressed. We hypothesized that occupancy of PRCs at the 15-LOX-1 promoter 
might contribute to the silencing of the gene in these cells. 
Several histone modifiers are reported to be the components of the PRCs, including the 
H3K27 demethylase UTX [216]. Thus we evaluated the expression level of UTX and 
its family member JMJD3. While Jmjd3 was hardly detectable, a relatively high level 
of UTX was detected in untreated A549 cells, although IL-4 treatment did not increase 
the expression. Interestingly, enrichment of UTX at the 15-LOX-1 promoter was 
observed upon IL-4 stimulation by using ChIP assay.  In order to investigate the 
importance of UTX in 15-LOX-1 expression mediated by histone modification, we 
transfected UTX specific siRNAs prior to IL-4 treatment, followed by qRT-PCR and 
ChIP assay. The results showed that inhibition of UTX not only attenuated 
demethylation of H3K27me3, but also reduced 15-LOX-1 induction by IL-4. This 
indicates that UTX is a key demethylase implicated in IL-4 mediated H3K27me3 
demethylation of the 15-LOX-1 promoter in A549 cells. Upon over-expression of UTX 
in A549 cells by transfecting a UTX expression vector, however, 15-LOX-1 expression 
was not induced, which indicates that global expression of UTX alone is insufficient to 
activate 15-LOX-1 transcription. Taken together, these results suggest that IL-4 
signaling mediates specific recruitment of UTX to the 15-LOX-1 promoter, and 
subsequent demethylation of H3K27me3 and 15-LOX-1 transcriptional activation.  
As 15-LOX-1 is one of the top IL-4-induced genes in human peripheral monocytes, we 
further performed the same analyses in monocytes. To assess the role of UTX in human 
monocytes, we inhibited UTX by using lentivector shRNA methodology. Analyses of 
these cells showed that the IL-4-induced transcription of 15-LOX-1 mRNA was 
significantly attenuated; indicating an important role of UTX in IL-4 induced 15-LOX-
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1 expression in human monocytes, as seen in A549 cells. However, IL-4 stimulation 
did not change the H3K27Me3 status at the 15-LOX-1 promoter, suggesting that UTX 
might also have an H3K27Me3-demethylase-independent regulatory function in terms 
of 15-LOX-1 induction in monocytes. Consistently, a histone demethylase-independent 
function of UTX was recently described in mice [217, 218]. 
Although these two cell models revealed distinct mechanisms of UTX action, the 
critical role of UTX was demonstrated.  In addition, L1236 was considered a useful 
model for investigating 15-LOX-1 regulation because of the constitutively expressed 
15-LOX-1. Both IL-13 and its active receptor IL-13R alpha1 are expressed in L1236 
cells, and the high expression level of 15-LOX-1 in L1236 cells is believed to be a 
consequence of the autocrine pathway mediated by IL-13. The potential role of UTX in 
the 15-LOX-1 regulation in L1236 cells was investigated. UTX depletion significantly 
inhibited the expression of 15-LOX-1, however, UTX knockdown did not markedly 
influence on the methylation level of H3K27, suggesting an H3K27Me3-demethylase-
independent regulatory function by UTX also in these cells. 
In summary, these findings illuminate the mechanisms involved in epigenetic 
regulation of 15-LOX-1 transcription mediated by IL-4/IL-13 stimulation. We 
demonstrate the critical role of UTX through specific H3K27me3 demethylation in 
A549 cells, and the results also suggest an H3K27Me3-demethylase-independent 
function of UTX in human monocytes and L1236 cells. Further studies aiming at 
characterization of the mechanisms associated with UTX H3K27Me3-demethylase-
independent activation of 15-LOX-1 are warranted.  
Collectively, a number of epigenetic mechanisms have been identified that are 
implicated in 15-LOX-1 transcriptional regulation, including DNA methylation, histone 
acetylation and histone methylation. How UTX finds its target promoter is still 
unknown. We attempted to pinpoint the potential interaction between UTX and STAT-
6 in 15-LOX-transactivation, however, it remains unclear if all these factors form a 
regulatory complex or modify the promoter sequentially.  Additionally, the results 
showed is that different cell types seem to have distinct machineries to control gene 
expression. 
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5 SUMMARY AND CONCLUSIONS 
In the present study, the crosstalk between infiltrating inflammatory cells and H-RS 
cells in the HL microenvironment was delineated by using in vitro cell models. The 
transcriptional regulation of a highly expressed inflammation-related enzyme, 15-LOX-
1 was assessed.  Several findings were demonstrated, including: 
1. The transcriptional factor EGR-1 mediates cytokine expression and secretion 
upon LTD4 challenge of L1236 cells, via the CysLT1 receptor. The CysLT1 
receptor was also detected in most primary H-RS cells, suggesting that LTD4, 
derived from surrounding cells, might contribute to the inflammatory 
microenvironment. Additionally, Mip-1α and Mip-1β were identified to be 
transcriptionally induced by LTD4 stimulation via the CysLT1 receptor.  
2. Several mechanisms involved in 15-LOX-1 regulation were identified. STAT-
6 has been proved to be an important transcription regulator of 15-LOX-1. 
Three putative STAT-6 binding motifs were predicted and were shown to be 
important for the full activation of 15-LOX-1 transcription. 
3. The STAT-6 accessibility was correlated with CpG methylation and histone 
acetylation of the 15-LOX-1 promoter, and consequently associated with 15-
LOX-1 transactivation. 
4. The histone H3 lysine (K)-4 specific methyltransferase SMYD3 plays a 
critical role in 15-LOX-1 activation in HL L1236 cells by modifying H3K4, 
while H3K4 demethylase SMCX inhibits 15-LOX-1 expression in L428 cells. 
Furthermore, the hypermethylated H3K4 is associated with histone 
hyperacetylation and STAT-6 binding, which leads to high expression of 15-
LOX-1. 
5. UTX is involved in epigenetic regulation 15-LOX-1 transcription mediated by 
IL-4 stimulation.  
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6 FUTURE PERSPECTIVES 
In the present study, the regulations of 15-LOX-1 was investigated, however, the 
biologic function of this enzyme in H-RS cells is still obscure. To identify the role of 
this enzyme, we have successfully knocked down 15-LOX-1 in L1236 cells, and 
established stable cell lines. Preliminary data reveal that 15-LOX-1 seems not to be 
required for L1236 survival and proliferation. However, due to the limitation of RNA 
interference, the expression of 15-LOX-1 cannot be totally shut down, thus the 
remaining protein might be sufficient for the cells to behave “normally”, although more 
than 80% knockdown efficiency was achieved.  One way to accomplish a total shut off 
could be the use of the cutting-edge technology termed RNA-guided clustered regularly 
interspaced shortpalindromic repeats (CRISPR), which modifies the gene at the 
genome level leading to complete gene silence [219, 220]. Additionally, the potential 
role of 15-LOX-1 in the accumulation of inflammatory cells in the HL 
microenvironment needs to be evaluated.  
During dendritic cell (DC) differentiation, 15-LOX-1 is one of the most induced genes 
[127, 221] however, the function of 15-LOX-1 during this process is unknown. Human 
15-LOX-1 has been suggested to play a critical role in cancer cell terminal 
differentiation [222-224] . Therefore, the biologic function of this enzyme in DCs, 
macrophages and mast cells is of great interest to depict. Our preliminary results 
support the hypothesis of role in differentiation. When we knocked down 15-LOX-1 in 
DCs, the maturation of the cells was remarkably disturbed. A future step of this project 
will be functional analysis to determine the role of 15-LOX-1 in DCs. 
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